Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.27 -2.8%	$0.27	$0.20 ▼ $1.48	$72.36M	2.18	1.62 million shs	386,996 shs
CRVS Corvus Pharmaceuticals	$4.17 -4.1%	$3.89	$1.96 ▼ $10.00	$284.27M	0.58	834,261 shs	434,657 shs
DBVT DBV Technologies	$10.16 -0.6%	$9.63	$2.20 ▼ $12.78	$278.28M	-0.59	190,526 shs	21,292 shs
SGMT Sagimet Biosciences	$9.49 +0.3%	$5.81	$1.73 ▼ $10.43	$291.06M	3.35	1.09 million shs	539,409 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+4.62%	+16.55%	+15.97%	+12.63%	-78.05%
CRVS Corvus Pharmaceuticals	+5.07%	+11.54%	+3.82%	+34.26%	+112.20%
DBVT DBV Technologies	-2.07%	-3.94%	+16.22%	+43.89%	+164.40%
SGMT Sagimet Biosciences	-0.11%	+8.99%	+14.39%	+335.94%	+184.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	1.8053 of 5 stars	3.1	4.0	1.6	0.8	0.0
CRVS Corvus Pharmaceuticals	2.8577 of 5 stars	3.5	1.0	3.3	3.3	0.6
DBVT DBV Technologies	3.9844 of 5 stars	4.4	5.0	2.3	2.5	0.6
SGMT Sagimet Biosciences	2.6415 of 5 stars	3.5	3.0	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	395.12% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	259.71% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	45.18% Upside
SGMT Sagimet Biosciences	3.00	Buy	$26.60	180.30% Upside

Current Analyst Ratings Breakdown

Latest ADAP, CRVS, SGMT, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.41	N/A	N/A	$0.05 per share	5.46
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
DBVT DBV Technologies	$4.15M	67.06	N/A	N/A	$1.42 per share	7.15
SGMT Sagimet Biosciences	$2M	145.53	N/A	N/A	$5.08 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.76	N/A	N/A	N/A	N/A	-35.21%	-34.09%	8/13/2025 (Estimated)

Latest ADAP, CRVS, SGMT, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
8/5/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
DBVT DBV Technologies	N/A	0.72	0.72
SGMT Sagimet Biosciences	N/A	20.34	20.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CRVS Corvus Pharmaceuticals	46.64%
DBVT DBV Technologies	71.74%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
CRVS Corvus Pharmaceuticals	31.30%
DBVT DBV Technologies	1.44%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	46.83 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

ADAP, CRVS, SGMT, and DBVT Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by Analysts

July 1, 2025 | marketbeat.com

SGMT Sagimet Biosciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Sagimet Biosciences Inc News (SGMT) - Investing.com

June 27, 2025 | investing.com

Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Sagimet Biosciences Inc.

June 14, 2025 | wsj.com

Sagimet Biosciences updates executive compensation

June 12, 2025 | investing.com

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

June 11, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...

June 11, 2025 | morningstar.comM

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

June 9, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 9, 2025 | globenewswire.com

Sagimet Biosciences Analyst Ratings

June 5, 2025 | benzinga.com

Sagimet Biosciences Shares Climb on Positive Clinical Trial Results for Acne Treatment

June 4, 2025 | marketwatch.com

Sagimet Biosciences shares soar on positive acne treatment trial results

June 4, 2025 | ca.investing.com

Sagimet partner Ascletis announces significant Phase III acne data

June 4, 2025 | thepharmaletter.comT

Sagimet Biosciences Shares Surge After Promising Phase 3 Acne Drug Results

June 4, 2025 | msn.com

Sagimet climbs as acne therapy hits main goals in late-stage trial in China

June 4, 2025 | msn.com

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

June 4, 2025 | aol.comA

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

June 4, 2025 | seekingalpha.com

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

June 4, 2025 | globenewswire.com

Sagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatment

May 24, 2025 | investing.com

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...

May 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, CRVS, SGMT, and DBVT Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 -0.01 (-2.85%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 +0.00 (+1.10%)

As of 06:13 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Corvus Pharmaceuticals NASDAQ:CRVS

$4.17 -0.18 (-4.14%)

Closing price 04:00 PM Eastern

Extended Trading

$4.19 +0.02 (+0.48%)

As of 05:03 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

DBV Technologies NASDAQ:DBVT

$9.82 -0.40 (-3.86%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Sagimet Biosciences NASDAQ:SGMT

$9.49 +0.03 (+0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$9.38 -0.11 (-1.16%)

As of 06:16 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time